USD 6.690.081.18%

CEO and President and Director

Mr. Rajiv De Silva is President Chief Executive Officer and a Director of Endo International Public Limited Company. Prior to joining Endo in March 2013 Mr. De Silva joined Endo Health Solutions as Chief Executive Officer and a Director in March 2013 and had served as the President of Valeant Pharmaceuticals International Inc. from October 2010 to January 2013 and served as its Chief Operating Officer Specialty Pharmaceuticals from January 2009 until January 2013. At Valeant he was responsible for all specialty pharmaceutical operations including sales and marketing research and development manufacturing and business development. Prior to joining Valeant Mr. De Silva held various leadership positions with Novartis. He served as President of Novartis Vaccines USA and Head Vaccines of the Americas at Novartis. During this time he played a key leadership role at Novartis Vaccines Diagnostics Division. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel Switzerland. Prior to his time at Novartis Mr. De Silva was a Principal at McKinsey Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. He has broad international experience having managed businesses in the United States Europe Canada Latin America Asia South Africa and AustraliaNew Zealand. Mr. De Silva was a Director of AMAG Pharmaceuticals Inc. and is currently a Member of the Board of Trustees at Kent Place School in Summit NJ.

Age: 48

353 1 268 2000 http://www.endo.com

De Silva was a Director of AMAG Pharmaceuticals, Inc., a public specialty pharmaceutical company, and is currently a Member of the Board of Trustees at Kent Place School in Summit, NJ. He holds a BS in Engineering, Honors from Princeton University, a MS from Stanford University and a MBA with Distinction from the Wharton School at the University of Pennsylvania.

Management Efficiency

The company has return on total asset (ROA) of 2.49 % which means that it generated profit of $2.49 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (126.01) % meaning that it created substantial loss on money invested by shareholders.

The company currently holds 8.28 B in liabilities. Endo International plc has Current Ratio of 1.06 suggesting that it is not liquid enough and may have problems to pay out its financial obligations when they are due.

Similar Executives

Found 1 records

CEO Since

Entity Summary

Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Endo International operates under Drug Manufacturers - Other classification in USA and traded on NASDAQ exchange. It employs 4894 people.Endo International plc (ENDP) is traded on NASDAQ in USA. It is located in IRELAND and employs 4,894 people. Endo International is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Transaction History Now

Transaction History

View history of all your transactions and understand their impact on performance

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Endo International plc to your portfolio